This presentation reports findings from the RHONE-X extension trial, which evaluated the long-term safety and efficacy of faricimab▼ in patients with DME who completed either of the 2-year randomized phase 3 clinical trials (YOSEMITE/RHINE). This is the largest DME extension study to date with over 1400 patients enrolled. We also present a case study of a patient who followed for 4 years and was treated with aflibercept in YOSEMITE and switched to faricimab▼ in RHONE-X.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.